Stories
Slash Boxes
Comments

SoylentNews is people

posted by martyb on Sunday November 28 2021, @02:10AM   Printer-friendly

An Alzheimer's Nasal Spray Vaccine Is About to Enter Human Trials For The First Time

Alzheimer's treatments seemed like an unlikely prospect mere months ago.

Drug trials tried and failed for 20 years to produce treatments that would stop the progression of the disease, and several large pharmaceutical companies abandoned the mission of developing Alzheimer's treatments altogether.

[...] Now, the field of Alzheimer's treatments may finally be opening up.

Last week, Brigham and Women's Hospital announced it would spearhead the first human trial of a nasal vaccine for Alzheimer's, designed to prevent or slow the disease's progression.

The trial is small – 16 people between ages 60 to 85 with Alzheimer's symptoms will receive two doses of the vaccine one week apart. But it builds on decades of research suggesting that stimulating the immune system can help clear out beta-amyloid plaques in the brain.

[...] The vaccine sprays a drug called Protollin directly into the nasal passage, with the goal of activating immune cells to remove the plaque.

FDA OKs Phase 1 Trial of Nasal Spray Immunotherapy Protollin

Protollin is a new intranasal immunotherapy made of proteins derived from the outer membrane of certain bacteria. It works by stimulating the innate immune system — the part of the immune system that serves as the body's first line of defense — to clear amyloid-beta plaques and tau tangles from the brain.

It worked in mice, so it must be good.

Also at Medical News Today.

Related: Novel Dementia Vaccine on Track for Human Trials Within Two Years


Original Submission

 
This discussion has been archived. No new comments can be posted.
Display Options Threshold/Breakthrough Mark All as Read Mark All as Unread
The Fine Print: The following comments are owned by whoever posted them. We are not responsible for them in any way.
  • (Score: 0, Troll) by krishnoid on Sunday November 28 2021, @03:27AM (2 children)

    by krishnoid (1156) on Sunday November 28 2021, @03:27AM (#1200151)

    The trial is small – 16 people between ages 60 to 85 with Alzheimer's symptoms will receive two doses of the vaccine one week apart. But it builds on decades of research suggesting that stimulating the immune system can help clear out beta-amyloid plaques in the brain.

    Kind of unusual to call mice "people", but if they've made it to 60 to 85, hey, they deserve it. Maybe that's in mouse years though. Hope they at least get a complimentary American Association of Rodent People membership with it.

    Starting Score:    1  point
    Moderation   -2  
       Troll=2, Total=2
    Extra 'Troll' Modifier   0  
    Karma-Bonus Modifier   +1  

    Total Score:   0  
  • (Score: 3, Informative) by Beryllium Sphere (r) on Sunday November 28 2021, @03:46AM (1 child)

    by Beryllium Sphere (r) (5062) on Sunday November 28 2021, @03:46AM (#1200154)

    The summary did say "first human trial".

    • (Score: 0) by Anonymous Coward on Sunday November 28 2021, @04:04PM

      by Anonymous Coward on Sunday November 28 2021, @04:04PM (#1200243)

      Phase 1 is safety only, to see if there are any major side effects. Nobody is looking at effects at this point - that's phase 2.